OM:2CUREX

Stock Analysis Report

Executive Summary

2cureX AB operates as a medtech company in Denmark.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has 2cureX's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

2CUREX

5.5%

SE Medical Equipment

2.1%

SE Market


1 Year Return

-3.8%

2CUREX

33.9%

SE Medical Equipment

12.1%

SE Market

Return vs Industry: 2CUREX underperformed the Swedish Medical Equipment industry which returned 33.9% over the past year.

Return vs Market: 2CUREX underperformed the Swedish Market which returned 12.1% over the past year.


Shareholder returns

2CUREXIndustryMarket
7 Day0.7%5.5%2.1%
30 Day3.7%1.8%1.6%
90 Day-13.1%2.6%3.8%
1 Year1.8%-3.8%35.4%33.9%16.8%12.1%
3 Yearn/a54.9%36.6%32.3%12.4%
5 Yearn/a72.9%44.6%62.9%28.4%

Price Volatility Vs. Market

How volatile is 2cureX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is 2cureX undervalued compared to its fair value and its price relative to the market?

5.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate 2CUREX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate 2CUREX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2CUREX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: 2CUREX is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 2CUREX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2CUREX is overvalued based on its PB Ratio (5.5x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is 2cureX forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as 2cureX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has 2cureX performed over the past 5 years?

12.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 2CUREX is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare 2CUREX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2CUREX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: 2CUREX has a negative Return on Equity (-17.74%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 2CUREX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 2CUREX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is 2cureX's financial position?


Financial Position Analysis

Short Term Liabilities: 2CUREX's short term assets (SEK37.6M) exceeds its short term liabilities (SEK7.2M)

Long Term Liabilities: 2CUREX has no long term liabilities


Debt to Equity History and Analysis

Debt Level: 2CUREX is debt free.

Reducing Debt: 2CUREX has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 2CUREX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2CUREX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2CUREX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2CUREX has sufficient cash runway for 1.226333 years if free cash flow continues to reduce at historical rates of -93.7% each year.


Next Steps

Dividend

What is 2cureX's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.6%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 2CUREX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2CUREX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 2CUREX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2CUREX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2CUREX's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of 2cureX's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Ole Thastrup (66yo)

0yrs

Tenure

kr750,000

Compensation

Mr. Ole Thastrup, VD Co-founded 2cureX AB in 2006 and serves as its Chief Executive Officer, Chairman and Member of Executive Board. Prior to 2cureX, Mr. Thastrup served as Head of Carlsberg Biosector and  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Ole's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Insufficient data to compare Ole's compensation with company performance.


Management Age and Tenure

1.3yrs

Average Tenure

56yo

Average Age

Experienced Management: 2CUREX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

2.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 2CUREX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ole Thastrup (66yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: kr750.00k
  • Timm Jessen (57yo)

    Co-Founder & Director

    • Tenure: 13.8yrs
  • Jürgen Kupper (54yo)

    Managing Director of GMBH

    • Tenure: 0yrs
  • Grith Hagel (60yo)

    Co-Founder & Head of Project Management

    • Tenure: 0yrs
  • Henrik Harling

    Chief Medical Officer

    • Tenure: 0.3yrs
  • Maarten van der Linden (50yo)

    Chief Business Officer

    • Tenure: 1.9yrs
  • Carit Andersen (55yo)

    Chief Financial Officer

    • Tenure: 0.8yrs

Board Members

  • Ole Thastrup (66yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: kr750.00k
  • Timm Jessen (57yo)

    Co-Founder & Director

    • Tenure: 13.8yrs
  • Jørgen Drejer (64yo)

    Director

    • Tenure: 2.8yrs
  • Nils Brünner (67yo)

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Povl-André Bendz (57yo)

    Chairman of the Board

    • Tenure: 2.8yrs
    • Compensation: kr9.62k
  • Andreas Block

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Dion Morton

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Camilla Bondesson (61yo)

    Director

    • Tenure: 0.5yrs

Company Information

2cureX AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 2cureX AB
  • Ticker: 2CUREX
  • Exchange: OM
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr173.259m
  • Shares outstanding: 12.42m
  • Website: https://www.2curex.com

Location

  • 2cureX AB
  • Building 8
  • 2. Tværvej
  • Copenhagen
  • Capital Region of Denmark
  • 2400
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2CUREXOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2017
2QEDB (Deutsche Boerse AG)YesShare CapitalDEEURNov 2017

Biography

2cureX AB operates as a medtech company in Denmark. It is involved in developing IndiTreat, a technology for the treatment of colorectal, ovarian, and kidney cancers. The company was founded in 2006 and is ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 21:34
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.